Development of molecular marker and novel therapy for FAP

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10154
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Hyogo Medical University
• Principal Investigator: Yamano Tomoki 兵庫医科大学, 医学部, 准教授 (00599318)
• Co-Investigator(Kenkyū-buntansha): 冨田 尚裕 兵庫医科大学, 医学部, 教授 (00252643) ; 久保 秀司 兵庫医科大学, 医学部, 准教授 (10441320)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 家族性大腸腺腫症 / マイクロRNA

Outline of Final Research Achievements

We looked for biomarker of FAP in plasma miRNA to detect existence of FAP and associated comorbidities. We compared plasma from five FAP patients before total proctocolectomy and three healthy volunteers using next generation sequence. Candidates included mir143-5p (7.6 times increase), mir143-3p (6.2 times increase), mir96-5p (10.9 times increase), mir183-5p (2.9 times increase), mir885-5p (one-eighth decrease). Among these candidates, we validated mir-143 because mir143-3p demonstrated high copy number in plasma. Decrease of mir143 in polyp of FAP patients was also reported. We measure relative expression of mir143 in eight FAP patients included three patients assessed by NGS. Relative expression of mir143 was 1.48, 1.28, 1.9, 1.46 and 0.76 in FAP patients before surgery. Relative expression of mir143 was 0.42, 0.44 and 0.2 in FAP patients after surgery. These data indicated mir143 expression might decrease after surgery, which meant polyposis influenced mir143 expression.

Free Research Field

外科腫瘍学